Importer of Controlled Substances Application: Fisher Clinical Services, Inc., 68671-68672 [2023-21972]

Download as PDF Federal Register / Vol. 88, No. 191 / Wednesday, October 4, 2023 / Notices DATES: September 5, 2023. FOR FURTHER INFORMATION CONTACT: lotter on DSK11XQN23PROD with NOTICES1 Kenneth Gatten III (202–708–1447), Office of Investigations, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436. Hearing-impaired persons can obtain information on this matter by contacting the Commission’s TDD terminal on 202– 205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at 202–205–2000. General information concerning the Commission may also be obtained by accessing its internet server (https:// www.usitc.gov). The public record for this proceeding may be viewed on the Commission’s electronic docket (EDIS) at https://edis.usitc.gov. SUPPLEMENTARY INFORMATION: Background.—On September 5, 2023, the Commission determined that the domestic interested party group response to its notice of institution (88 FR 35926, June 1, 2023) of the subject five-year review was adequate and that the respondent interested party group response was inadequate. The Commission did not find any other circumstances that would warrant conducting a full review.1 Accordingly, the Commission determined that it would conduct an expedited review pursuant to section 751(c)(3) of the Act (19 U.S.C. 1675(c)(3)).2 For further information concerning the conduct of this review and rules of general application, consult the Commission’s Rules of Practice and Procedure, part 201, subparts A and B (19 CFR part 201), and part 207, subparts A, D, E, and F (19 CFR part 207). Staff report.—A staff report containing information concerning the subject matter of the review has been placed in the nonpublic record, and will be made available to persons on the Administrative Protective Order service list for this review on October 18, 2023. A public version will be issued thereafter, pursuant to § 207.62(d)(4) of the Commission’s rules. Written submissions.—As provided in § 207.62(d) of the Commission’s rules, interested parties that are parties to the review and that have provided individually adequate responses to the notice of institution,3 and any party other than an interested party to the review may file written comments with the Secretary on what determination the Commission should reach in the review. Comments are due on or before 5:15 p.m. on October 26, 2023, and may not contain new factual information. Any person that is neither a party to the fiveyear review nor an interested party may submit a brief written statement (which shall not contain any new factual information) pertinent to the review by October 26, 2023. However, should the Department of Commerce (‘‘Commerce’’) extend the time limit for its completion of the final results of its review, the deadline for comments (which may not contain new factual information) on Commerce’s final results is three business days after the issuance of Commerce’s results. If comments contain business proprietary information (BPI), they must conform with the requirements of §§ 201.6, 207.3, and 207.7 of the Commission’s rules. The Commission’s Handbook on Filing Procedures, available on the Commission’s website at https:// www.usitc.gov/documents/handbook_ on_filing_procedures.pdf, elaborates upon the Commission’s procedures with respect to filings. In accordance with §§ 201.16(c) and 207.3 of the rules, each document filed by a party to the review must be served on all other parties to the review (as identified by either the public or BPI service list), and a certificate of service must be timely filed. The Secretary will not accept a document for filing without a certificate of service. Determination.—The Commission has determined this review is extraordinarily complicated and therefore has determined to exercise its authority to extend the review period by up to 90 days pursuant to 19 U.S.C. 1675(c)(5)(B). Authority: This review is being conducted under authority of title VII of the Act; this notice is published pursuant to § 207.62 of the Commission’s rules. By order of the Commission. Issued: September 29, 2023. Lisa Barton, Secretary to the Commission. [FR Doc. 2023–22065 Filed 10–3–23; 8:45 am] BILLING CODE 7020–02–P 1A record of the Commissioners’ votes, the Commission’s statement on adequacy, and any individual Commissioner’s statements will be available from the Office of the Secretary and at the Commission’s website. 2 Chairman David S. Johanson and Commissioner Rhonda K. Schmidtlein voted to conduct full a review. VerDate Sep<11>2014 20:21 Oct 03, 2023 Jkt 262001 3 The Commission has found the responses submitted on behalf of ADA Carbon Solutions, LLC, Calgon Carbon Corporation, Carbon Activated Corporation, Jacobi Carbons, Inc., and Norit Americas, Inc. to be individually adequate. Comments from other interested parties will not be accepted (see 19 CFR 207.62(d)(2)). PO 00000 Frm 00113 Fmt 4703 Sfmt 4703 68671 DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–1275] Importer of Controlled Substances Application: Fisher Clinical Services, Inc. Drug Enforcement Administration, Justice. ACTION: Notice of application. AGENCY: Fisher Clinical Services, Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before November 3, 2023. Such persons may also file a written request for a hearing on the application on or before November 3, 2023. ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on August 15, 2023, Fisher Clinical Services, Inc., 700A–C Nestle Way, Breinigsville, Pennsylvania 18031–1522, applied to be registered as an importer of the following basic class(es) of controlled substance(s): SUMMARY: E:\FR\FM\04OCN1.SGM 04OCN1 68672 Federal Register / Vol. 88, No. 191 / Wednesday, October 4, 2023 / Notices Controlled substance Drug code Marihuana Extract ...... Psilocybin ................... Methylphenidate ......... Levorphanol ............... Noroxymorphone ....... Tapentadol ................. 7350 7437 1724 9220 9668 9780 Schedule I I II II II II The company plans to import the listed controlled substances for use in clinical trials only. No other activities for these drug codes are authorized for this registration. Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or nonapproved finished dosage forms for commercial sale. Decree for thirty (30) days from the date of publication of this Notice. Please address comments to Phillip R. Dupre´, Post Office Box 7611, Washington, DC 20044 and/or pubcomment_eds.enrd@ usdoj.gov and refer to United States v. Shell Oil Co., DJ No. 90–11–6–21352. The proposed Amendment to the Consent Decree may be examined at the Clerk’s Office, United States District Court for the District of Colorado, 901 19th Street, Denver, CO 80294. In addition, the proposed Consent Decree may be examined electronically at https://www.justice.gov/enrd/consentdecrees. Cherie Rogers, Assistant Section Chief, Environmental Defense Section, Environment and Natural Resources Division. [FR Doc. 2023–21961 Filed 10–3–23; 8:45 am] BILLING CODE P Claude Redd, Acting Deputy Assistant Administrator. DEPARTMENT OF JUSTICE Notice of Lodging of Proposed Consent Decree DEPARTMENT OF JUSTICE lotter on DSK11XQN23PROD with NOTICES1 Notice of Lodging of Proposed Consent Decree In accordance with Departmental Policy, 28 CFR 50.7, section 122(d)(2) of the Comprehensive Environmental Response, Compensation, and Liability Act (‘‘CERCLA’’), 42 U.S.C. 9622(d)(2), and Paragraph 4.1 of the underlying Consent Decree, notice is hereby given that a proposed Amendment to the Consent Decree in United States v. Shell Oil. Co., Case No. 83-cv-2379, was lodged with the United States District Court for the District of Colorado on September 28, 2023. Previously, a Consent Decree resolving claims under CERCLA related to the former Rocky Mountain Arsenal outside of Denver, Colorado between the parties was entered in this case on February 12, 1993. That Consent Decree incorporated a February 12, 1989, Settlement Agreement between the United States and Shell Oil. Under the Consent Decree, the Army and Shell Oil are obligated to pay the Environmental Protection Agency’s CERCLA oversight costs for Army-led environmental cleanup activities at the Rocky Mountain Arsenal. The proposed Amendment to the Consent Decree changes the manner in which the Environmental Protection Agency’s CERCLA oversight costs will be paid, and fully resolves those costs. The Department of Justice will accept written comments relating to this proposed Amendment to the Consent Jkt 262001 [FR Doc. 2023–21966 Filed 10–3–23; 8:45 am] BILLING CODE P DEPARTMENT OF JUSTICE [OMB Number 1105–0109] Agency Information Collection Activities; Proposed eCollection eComments Requested; Procurement Collusion Strike Force Complaint Form Antitrust Division, Department of Justice. ACTION: 30-Day notice. BILLING CODE 4410–09–P 20:21 Oct 03, 2023 Cherie Rogers, Assistant Section Chief, Environmental Defense Section, Environment and Natural Resources Division. AGENCY: [FR Doc. 2023–21972 Filed 10–3–23; 8:45 am] VerDate Sep<11>2014 District of West Virginia, located at 500 West Pike Street, Room 301, Clarksburg, WV 26301. In addition, the proposed Consent Decree may be examined electronically at https:// www.justice.gov/enrd/consent-decrees. In accordance with Departmental Policy, 28 CFR 50.7, notice is hereby given that a proposed Consent Decree in United States, et al. v. Waco Oil & Gas Co., Inc., Civil Action No. 23–cv–00078, was lodged with the United States District Court for the Northern District of West Virginia on September 28, 2023. This proposed Consent Decree concerns a complaint filed by the United States and the State of West Virginia against Defendant Waco Oil & Gas Co., Inc., pursuant to Section 309(b) and (d) of the Clean Water Act, 33 U.S.C. 1319(b) and (d), to obtain injunctive relief from and impose civil penalties against the Defendant for violating the Clean Water Act by discharging pollutants without a permit into waters of the United States. The proposed Consent Decree resolves these allegations by requiring the Defendant to restore impacted areas, perform mitigation, and pay a civil penalty. The Department of Justice will accept written comments relating to this proposed Consent Decree for thirty (30) days from the date of publication of this Notice. Please address comments by email to pubcomment_eds.enrd@ usdoj.gov or by mail to Albert Lin, Environment and Natural Resources Division, Environmental Defense Section, Post Office Box 7611, Washington, DC 20044–7611; and refer to United States, et al. v. Waco Oil & Gas Co., Inc., DJ No. 90–5–1–1–22046. The proposed Consent Decree may be examined at the Clerk’s Office, United States District Court for the Northern PO 00000 Frm 00114 Fmt 4703 Sfmt 4703 The Antitrust Division, Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection was previously published in the Federal Register on August 1, 2023, allowing a 60-day comment period. DATES: Comments are encouraged and will be accepted for 30 days until November 3, 2023. FOR FURTHER INFORMATION CONTACT: If you have comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact: sarah.oldfield@usdoj.gov; telephone: 202–305–8915. SUPPLEMENTARY INFORMATION: Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; —Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; SUMMARY: E:\FR\FM\04OCN1.SGM 04OCN1

Agencies

[Federal Register Volume 88, Number 191 (Wednesday, October 4, 2023)]
[Notices]
[Pages 68671-68672]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-21972]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-1275]


Importer of Controlled Substances Application: Fisher Clinical 
Services, Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Fisher Clinical Services, Inc. has applied to be registered as 
an importer of basic class(es) of controlled substance(s). Refer to 
SUPPLEMENTARY INFORMATION listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may submit electronic comments on or 
objections to the issuance of the proposed registration on or before 
November 3, 2023. Such persons may also file a written request for a 
hearing on the application on or before November 3, 2023.

ADDRESSES: The Drug Enforcement Administration requires that all 
comments be submitted electronically through the Federal eRulemaking 
Portal, which provides the ability to type short comments directly into 
the comment field on the web page or attach a file for lengthier 
comments. Please go to https://www.regulations.gov and follow the 
online instructions at that site for submitting comments. Upon 
submission of your comment, you will receive a Comment Tracking Number. 
Please be aware that submitted comments are not instantaneously 
available for public view on https://www.regulations.gov. If you have 
received a Comment Tracking Number, your comment has been successfully 
submitted and there is no need to resubmit the same comment. All 
requests for a hearing must be sent to: (1) Drug Enforcement 
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, 
Springfield, Virginia 22152; and (2) Drug Enforcement Administration, 
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, 
Springfield, Virginia 22152. All requests for a hearing should also be 
sent to: Drug Enforcement Administration, Attn: Administrator, 8701 
Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this 
is notice that on August 15, 2023, Fisher Clinical Services, Inc., 
700A-C Nestle Way, Breinigsville, Pennsylvania 18031-1522, applied to 
be registered as an importer of the following basic class(es) of 
controlled substance(s):

[[Page 68672]]



------------------------------------------------------------------------
        Controlled substance             Drug code         Schedule
------------------------------------------------------------------------
Marihuana Extract...................            7350  I
Psilocybin..........................            7437  I
Methylphenidate.....................            1724  II
Levorphanol.........................            9220  II
Noroxymorphone......................            9668  II
Tapentadol..........................            9780  II
------------------------------------------------------------------------

    The company plans to import the listed controlled substances for 
use in clinical trials only. No other activities for these drug codes 
are authorized for this registration.
    Approval of permit applications will occur only when the 
registrant's business activity is consistent with what is authorized 
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import 
of Food and Drug Administration-approved or non-approved finished 
dosage forms for commercial sale.

Claude Redd,
Acting Deputy Assistant Administrator.
[FR Doc. 2023-21972 Filed 10-3-23; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.